文献速递消化道肿瘤放疗胸部肿瘤放疗放疗物理与技术

食管癌术前放化疗中心脏与肺受照剂量对总生存的影响:CALGB 80803事后分析

The Impact of Lung and Heart Radiation Dose During Preoperative Chemoradiation on Overall Survival in Esophageal Cancer-A Post Hoc Analysis of CALGB 80803 (Alliance).
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2026-02-05

该研究对CALGB 80803(Alliance)前瞻性研究进行事后分析,评估食管癌术前放化疗中心脏和肺受照剂量与总生存(OS)的关系,并分析IMRT对方案剂量约束依从性的影响。结果显示多数患者IMRT计划满足总肺和心脏剂量约束,心脏V30 Gy≤21%与OS改善相关,多因素分析中肺V10 Gy>42%和心脏V30 Gy>21%均与更差OS相关。

要点

  • 多因素分析:肺V10 Gy>42%(HR 1.71)和心脏V30 Gy>21%(HR 1.86)与更差OS相关。

核心结论

  • 最小化肺低剂量体积(V10 Gy)和心脏V30 Gy与显著生存获益相关。
  • 设计食管癌放疗计划时应考虑总肺V10 Gy≤42%、心脏V30 Gy≤21%,并优先选用IMRT而非3D-CRT。

研究设计与样本

  • CALGB 80803(Alliance)前瞻性研究的事后分析,共225例患者接受诱导化疗,209/225(92.8%)有放疗模式数据。
  • 方案规定的剂量约束为:总肺V10 Gy≤40%、V20 Gy≤20%、V30 Gy≤15%、V40 Gy≤10%;心脏V30 Gy≤30%。
  • 事后分析计算了最能区分OS的剂量切点。

主要发现

  • 127/209(60.9%)接受IMRT治疗。
  • 方案剂量约束依从率分别为:总肺V10 Gy 162/209(77.5%)、V20 Gy 179/209(85.6%)、V30 Gy 207/209(99.0%)、V40 Gy 208/209(99.5%)、心脏V30 Gy 158/209(75.6%)。

关键数值与推荐

  • 方案规定总肺V10 Gy≤40%、V20 Gy≤20%、V30 Gy≤15%、V40 Gy≤10%,心脏V30 Gy≤30%。
  • 事后分析提示总肺V10 Gy≤42%和心脏V30 Gy≤21%与生存获益相关。

临床怎么用

  • 食管癌放疗计划设计时应尽量将总肺V10 Gy控制在≤42%、心脏V30 Gy控制在≤21%。
  • 优先采用IMRT而非3D-CRT以降低心脏V30 Gy等剂量参数。

局限性

  • 本研究为CALGB 80803的事后分析,剂量切点为事后计算,需前瞻性验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Although technical advances have allowed for reduced radiation doses to the lungs and heart when treating esophageal cancer, doses to these organs cannot yet be eliminated completely. We conducted a post hoc analysis of CALGB 80803 (Alliance) to evaluate whether the radiation doses delivered to the heart and lungs in a prospective study with robust quality assurance were associated with overall survival (OS), and we assessed the impact of intensity modulated radiation therapy (IMRT) on adherence with protocol-specified dose constraints. METHODS AND MATERIALS: Protocol-specified dose constraints were based on standard of care guidelines: total lung V10 Gy ≤ 40%, V20 Gy ≤ 20%, V30 Gy ≤ 15%, V40 Gy ≤ 10%; heart V30 Gy ≤ 30%. Post hoc dose cutpoints were calculated that best differentiated OS. RESULTS: A total of 225 patients underwent induction chemotherapy, where radiation modality data were available for 209/225 (92.8%); 127/209 (60.9%) were treated with IMRT. Adherence rates were high for each of the protocol-specified dose constraints: 162/209 (77.5%), 179/209 (85.6%), 207/209 (99.0%), 208/209 (99.5%), and 158/209 (75.6%); total lung: V10 Gy, V20 Gy, V30 Gy, V40 Gy, and heart V30 Gy, respectively. The heart V30 Gy ≤ 21% (P = .016) was associated with improved OS. Among patients with heart V30 Gy ≤ 21%, 8.5% and 32.3% received 3-dimensional conformal radiation therapy (3D-CRT) and IMRT, respectively (P < .001). Mean heart V30 Gy was lower in the IMRT versus the 3D-CRT group (24.7 vs 35.6; P < .001). On multivariable analysis, lung V10 Gy > 42% (hazard ratio [HR], 1.71; P = .017) and heart V30 Gy > 21% (HR, 1.86; P = .013) were associated with worse OS. CONCLUSIONS: Most patients on CALGB 80803 (Alliance) were treated with IMRT plans that met protocol-specified dose constraints for total lung and heart. Minimizing low dose volume to the lungs (V10 Gy) and minimizing heart V30 Gy were associated with a significant survival benefit. Total lung V10 Gy ≤ 42% and heart V30 Gy ≤ 21%, and utilization of IMRT over 3D-CRT, should be considered when designing radiation plans for patients with esophageal cancer.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Lehrer EJ, Geyer S, Goodrich A, et al. The Impact of Lung and Heart Radiation Dose During Preoperative Chemoradiation on Overall Survival in Esophageal Cancer-A Post Hoc Analysis of CALGB 80803 (Alliance). Int J Radiat Oncol Biol Phys. 2026. PMID: 41653999. doi:10.1016/j.ijrobp.2026.01.032

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。